论文部分内容阅读
近年来可溶性白细胞介素-2(SIL-2R)的研究已发展到应用于临床.据报道血清sIL-2R增高可见于白血病,获得性免疫缺陷、器官移植及肉芽肿性疾病.但用于消化道癌病情变化之监测还较少.本文测定63例消化道癌者血清sIL-2R水平,并对结果分析,以探讨其对消化道癌病情变化、发展及预后的关系.1 材料与方法1.1 对象 消化道癌组63例,男48例,女15例,年龄28～80岁.中位值63岁,其中食道癌28例,胃癌18例,大肠癌17例.57例经食道拉网或胃、肠内镜活检或手术后病理确诊,6例食道癌经X线钡餐、CT及临床证实.采血前一月未放、化疗.消化道良
In recent years, the study of soluble interleukin-2 (SIL-2R) has been developed into clinical applications. It has been reported that increased serum sIL-2R is found in leukemia, acquired immunodeficiency, organ transplantation, and granulomatous disease. However, it is used for digestion. There is less monitoring of changes in cancer status. Serum levels of sIL-2R in 63 patients with digestive tract cancer were determined in this study, and the results were analyzed to investigate their relationship to changes in the status, development and prognosis of gastrointestinal cancer.1 Materials and methods 1.1 Subjects Digestive tract cancer group 63 patients, 48 males and 15 females, aged 28 to 80 years. The median value was 63 years old, including 28 cases of esophageal cancer, 18 cases of gastric cancer, 17 cases of colorectal cancer, 57 cases of transesophageal pull or Gastric, intestinal endoscopic biopsy or postoperative pathological diagnosis, 6 cases of esophageal cancer by X-ray barium meal, CT and clinical confirmation. Before the blood collection, chemotherapy, good digestive tract